297 related articles for article (PubMed ID: 24309327)
1. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
[TBL] [Abstract][Full Text] [Related]
3. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
5. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
[TBL] [Abstract][Full Text] [Related]
6. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
7. ASPSCR1-TFE3 fusion in a case of Xp11 translocation PEComa of the liver: are ASPSCR1-TFE3 fusion-bearing tumours Xp11 translocation PEComa or alveolar soft part sarcoma?
Chai J; Ma J; Liu Y; Zhao D; Yin Z; Wang Z; Fan L
Pathology; 2023 Apr; 55(3):416-419. PubMed ID: 36104270
[No Abstract] [Full Text] [Related]
8. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
10. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
[TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity of TFE3 activation in renal cell carcinomas.
Macher-Goeppinger S; Roth W; Wagener N; Hohenfellner M; Penzel R; Haferkamp A; Schirmacher P; Aulmann S
Mod Pathol; 2012 Feb; 25(2):308-15. PubMed ID: 22037260
[TBL] [Abstract][Full Text] [Related]
12. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
13. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
14. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.
Argani P; Olgac S; Tickoo SK; Goldfischer M; Moch H; Chan DY; Eble JN; Bonsib SM; Jimeno M; Lloreta J; Billis A; Hicks J; De Marzo AM; Reuter VE; Ladanyi M
Am J Surg Pathol; 2007 Aug; 31(8):1149-60. PubMed ID: 17667536
[TBL] [Abstract][Full Text] [Related]
15. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
[TBL] [Abstract][Full Text] [Related]
16. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).
Argani P; Antonescu CR; Couturier J; Fournet JC; Sciot R; Debiec-Rychter M; Hutchinson B; Reuter VE; Boccon-Gibod L; Timmons C; Hafez N; Ladanyi M
Am J Surg Pathol; 2002 Dec; 26(12):1553-66. PubMed ID: 12459622
[TBL] [Abstract][Full Text] [Related]
17. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
18. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
[TBL] [Abstract][Full Text] [Related]
19. [The translocation carcinoma: A pediatric renal tumor also in adults].
Bruder E; Moch H
Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
[TBL] [Abstract][Full Text] [Related]
20. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]